83 yo Woman With Elevated Anti-Thyroid Antibodies and AMS

Isabel Casimiro, MD PhD
Endorama Sept 2018
Objectives

• Discuss the role of anti-thyroid antibodies in thyroid disease & non-thyroidal illness

• Understand the pathophysiology and treatment of encephalopathy associated with autoimmune thyroiditis
HPI

• 8/5/17: Admitted at OSH for AMS/confusion (baseline normal cognition)
• 2-3 wks Hx of progressive disorientation, agitation, paranoia, & echolalia (repeatedly saying “seven”)
• Sodium found to be 119 on admission improved to 125 prior to transfer
• Was on broad spectrum Abx for WBC 20.1 (concern for PNA vs meningitis)
• 8/7/17: normal LP, normal MRI brain
• 8/8/17: Abx d/c’d, Na and WBC improved; EEG: right PLEDs (periodic lateralized epileptiform discharges) -> transferred to Neuro ICU
• 8/12/17 new hyperintensity along the cortex of the R posterior inferior temporal lobe, inferior lateral frontal & parietal lobes, R insula & R posterior thalamus along w R hippocampus, no evidence of metastatic or meningeal dz
• Transferred to U of C on 8/16/17 for further work up
• Abnormal thyroid function tests on admission, Endo consulted
PMH
• Adenocarcinoma of the breast s/p mastectomy (2017), chemo
• IBS
• CAD
• HTN
• Depression, anxiety
• HLD
• Hashimoto’s thyroiditis (?)
• Gout

FH
• Son: Bipolar dz
• Sister: breast cancer

SH
• Pt lives with son. She worked for the post office before retirement in 1997.
• No EtOH or IVDU
Meds*

*Meds started this hospitalization

- Acyclovir 600mg Q8hr
- Famotidine 20mg Qd
- Heparin 5000 UQ8hr
- Novolog SSI 2-10 U Q6hr prn
- Levetiracetam/Keppra 1000mg Q12h
- Lorazepam/Ativan 1mg Q15 min prn
- Phenytoin/Dilantin 100mg Q8hr

PTA Meds:

- Amlodipine
- ASA
- Letrozole
- Lisinopril
- Simvastatin
- Clonazepam
- Escitalopram
Physical Exam on U of C Admission

- **General:** Patient is non-responsive, but in no acute distress
- **HEENT:** NC/AT, conjunctiva pink, sclera white, oropharynx pink and moist
- **CV:** RRR, no murmurs
- **LUNGS:** CTA bilaterally
- **ABD:** BS+, mildly distended, no apparent pain to palpation
- **EXT:** no C/C/E, extremities warm
- **SKIN:** no rashes or bruising or ulcers
- **Neuro:** **Motor:** No spontaneous movements; Increased tone in all extremities; No rhythmic or myoclonic movements are evident

<table>
<thead>
<tr>
<th>Reflexes: Hypertonic, reflexes hard to obtain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biceps</td>
</tr>
<tr>
<td>Triceps</td>
</tr>
<tr>
<td>BR</td>
</tr>
<tr>
<td>Patella</td>
</tr>
<tr>
<td>Ankles</td>
</tr>
<tr>
<td>Plantar response</td>
</tr>
<tr>
<td>Hoffmans</td>
</tr>
<tr>
<td>Ankle clonus</td>
</tr>
</tbody>
</table>

| Vitals: BP: 124/58, HR: 67, T 36.8, RR: 24, Wt 59.2kg 130 lb |
Labs

Calcium: 8.3
Phos: 2.9
Mag: 1.6

Protein: 5.3
Albumin: 2.7
Tbili: 0.3
Alk phos: 47
AST: 41
ALT: 25
CK: 642

TSH: 4.47 (0.3 - 4)
FT4: 0.94 (0.9 - 1.7)
T3: 64 (80 - 195)
Cortisol (03:16am): 10.7
Thyroid function tests in nonthyroidal illness

Schematic representation of the changes in thyroid function tests in patients with nonthyroidal illness of increasing severity.
Labs

- TSH: 4.47 (0.3 - 4)
- FT4: 0.94 (0.9 - 1.7)
- T3: 64 (80 - 195)
- Cortisol (03:16am): 10.7

- Calcium: 8.3
- Phos: 2.9
- Mag: 1.6
- Protein: 5.3
- Albumin: 2.7
- Tbili: 0.3
- Alk phos: 47
- AST: 41
- ALT: 25
- CK: 642
- TSH: 4.47 (0.3 - 4)
- FT4: 0.94 (0.9 - 1.7)
- T3: 64 (80 - 195)
- Cortisol (03:16am): 10.7
Labs

Calcium: 8.3
Phos: 2.9
Mag: 1.6

Anti-Tg:>30 (200x: 1860)
Anti-TPO>20 (440)
TG by MS: 565

Protein: 5.3
Albumin 2.7
Tbili: 0.3
Alk phos: 47
AST: 41
ALT: 25
CK: 642

TSH: 4.47 (0.3 -4)
FT4: 0.94 (0.9 -1.7)
T3: 64 (80 -195)
Cortisol (03:16am) 10.7
Consult Question:
Does Pt have Hashimoto’s encephalitis?

- Labs
  - TSH: 4.47 (0.3 - 4)
  - FT4: 0.94 (0.9 - 1.7)
  - T3: 64 (80 - 195)
  - Cortisol (03:16am): 10.7
  - Calcium: 8.3
  - Phos: 2.9
  - Mag: 1.6
  - Anti-Tg: >30 (200x: 1860)
  - Anti-TPO: >20 (440)
  - TG by MS: 565
  - AST: 41
  - ALT: 25
  - CK: 642
  - AST: 4.47 (0.3 - 4)
  - FT4: 0.94 (0.9 - 1.7)
  - T3: 64 (80 - 195)
  - Cortisol (03:16am): 10.7
Hashimoto’s Encephalopathy (HE)
Hashimoto’s Encephalopathy (HE)

• Originally described in 1966, it remains a somewhat controversial disorder; ~ 100 cases described worldwide
• AKA Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) or nonvasculitic autoimmune meningoencephalitis
• Characterized by subacute onset of confusion with altered level of consciousness, seizures, and myoclonus
  • Diagnostic criteria proposed by Peschen-Rosin 1999: seizures, psychiatric dz, focal neuro deficits with elevated thyroid Abs & excellent response to steroids
• Believed to be an immune-mediated disorder rather than representing the direct effect of an altered thyroid state on the CNS
## Anti-thyroid Antibodies

<table>
<thead>
<tr>
<th>Group</th>
<th>Anti-TSHR Ab</th>
<th>Anti-Tg Ab</th>
<th>Anti-TPO Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td>General population</td>
<td>0</td>
<td>5 to 20</td>
<td>8 to 27</td>
</tr>
<tr>
<td>Graves’ disease</td>
<td>80 to 95</td>
<td>50 to 70</td>
<td>50 to 80</td>
</tr>
<tr>
<td>Autoimmune thyroiditis</td>
<td>10 to 20</td>
<td>80 to 90</td>
<td>90 to 100</td>
</tr>
</tbody>
</table>

/Hashimoto’s thyroiditis
## Anti-thyroid Antibodies

<table>
<thead>
<tr>
<th>Group</th>
<th>Anti-TSHR Ab</th>
<th>Anti-Tg Ab</th>
<th>Anti-TPO Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td>General population</td>
<td>0</td>
<td>5 to 20</td>
<td>8 to 27</td>
</tr>
<tr>
<td>Graves’ disease</td>
<td>80 to 95</td>
<td>50 to 70</td>
<td>50 to 80</td>
</tr>
<tr>
<td>Autoimmune thyroiditis /Hashimoto’s thyroiditis</td>
<td>10 to 20</td>
<td>80 to 90</td>
<td>90 to 100</td>
</tr>
<tr>
<td>Relatives of patients with autoimmune thyroiditis</td>
<td>0</td>
<td>30 to 50</td>
<td>30 to 50</td>
</tr>
</tbody>
</table>
### Estimated prevalence of antithyroid antibodies (in percent)

<table>
<thead>
<tr>
<th>Group</th>
<th>Anti-TSHR Ab</th>
<th>Anti-Tg Ab</th>
<th>Anti-TPO Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td>General population</td>
<td>0</td>
<td>5 to 20</td>
<td>8 to 27</td>
</tr>
<tr>
<td>Graves’ disease</td>
<td>80 to 95</td>
<td>50 to 70</td>
<td>50 to 80</td>
</tr>
<tr>
<td>Autoimmune thyroiditis / Hashimoto’s thyroiditis</td>
<td>10 to 20</td>
<td>80 to 90</td>
<td>90 to 100</td>
</tr>
<tr>
<td>Relatives of patients with autoimmune thyroiditis</td>
<td>0</td>
<td>30 to 50</td>
<td>30 to 50</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>0</td>
<td>30 to 40</td>
<td>30 to 40</td>
</tr>
</tbody>
</table>
## Anti-thyroid Antibodies

<table>
<thead>
<tr>
<th>Group</th>
<th>Anti-TSHR Ab</th>
<th>Anti-Tg Ab</th>
<th>Anti-TPO Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td>General population</td>
<td>0</td>
<td>5 to 20</td>
<td>8 to 27</td>
</tr>
<tr>
<td>Graves’ disease</td>
<td><strong>80 to 95</strong></td>
<td>50 to 70</td>
<td>50 to 80</td>
</tr>
<tr>
<td>Autoimmune thyroiditis (Hashimoto’s thyroiditis)</td>
<td>10 to 20</td>
<td><strong>80 to 90</strong></td>
<td><strong>90 to 100</strong></td>
</tr>
<tr>
<td>Relatives of patients with autoimmune thyroiditis</td>
<td>0</td>
<td>30 to 50</td>
<td>30 to 50</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>0</td>
<td>30 to 40</td>
<td>30 to 40</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>0</td>
<td>about 14</td>
<td>about 14</td>
</tr>
</tbody>
</table>
## Anti-thyroid Antibodies

### Estimated prevalence of antithyroid antibodies (in percent)

<table>
<thead>
<tr>
<th>Group</th>
<th>Anti-TSHR Ab</th>
<th>Anti-Tg Ab</th>
<th>Anti-TPO Ab</th>
</tr>
</thead>
<tbody>
<tr>
<td>General population</td>
<td>0</td>
<td>5 to 20</td>
<td>8 to 27</td>
</tr>
<tr>
<td>Graves’ disease</td>
<td>80 to 95</td>
<td>50 to 70</td>
<td>50 to 80</td>
</tr>
<tr>
<td>Autoimmune thyroiditis/Hashimoto’s thyroiditis</td>
<td>10 to 20</td>
<td>80 to 90</td>
<td>90 to 100</td>
</tr>
<tr>
<td>Relatives of patients with autoimmune thyroiditis</td>
<td>0</td>
<td>30 to 50</td>
<td>30 to 50</td>
</tr>
<tr>
<td>Type 1 diabetes</td>
<td>0</td>
<td>30 to 40</td>
<td>30 to 40</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>0</td>
<td>about 14</td>
<td>about 14</td>
</tr>
</tbody>
</table>

Anti-TSHR Ab: anti-thyroid-stimulating hormone receptor antibodies; anti-Tg Ab: anti-thyroglobulin antibodies; anti-TPO Ab: anti-thyroid peroxidase antibodies.

Healthy people: 11% anti-TG, 13% anti-TPO
Anti-thyroid Antibodies in Non-thyroidal Illness

FIGURE 3 | Overview of extra-thyroidal effects of anti-thyroid antibodies.
History of TSH Receptor Ab: TRAb

- TSHR autoantibodies were discovered in 1956 by Adams & Purves and were called long-acting thyroid stimulator (LATS)
  - The presence of these antibodies were detected in patients with Graves’ disease
  - 20 years later, the exact binding site for the TSHR antibodies was described; the leucine rich domain of the A subunit of TSHR (same binding site for TSH)
  - Stimulation of TSH by GD-TRAb’s leads to activation of adenylate cyclase leading to cAMP generation, which eventually lead to T4 and T3 release
- The A subunit is shed which is thought to be important in the generation of autoimmunity in GD

TSH Receptor (Olga et al., JBM 2017)
Graves Disease

• Syndrome of hyperthyroidism caused by autoimmunity; extrathyroidal manifestations can include eye disease (Graves ophthalmopathy), dermopathy (pretibial myxedema/Graves dermopathy), and/or goiter

• Symptoms of hyperthyroidism: weight loss, weakness, dyspnea, palpitations, increased hunger/thirst, hyperdefecation, sweating, sensitivity to heat, tremor, irritability, menstrual irregularity

• Activating autoantibodies to TRAb stimulate thyroid hormone synthesis and secretion as well as sometimes thyroid growth (goiter)

• In the assessment of TSH receptor autoimmunity three types of TSH receptor antibodies (TRAbs) can be measured:
  • TSAb: stimulating TRAbs (Graves dz)
  • TBAb: blocking TRAbs (extrathyroidal GD manifestations, also seen in hypothyroidism)
  • Neutral Abs: unknown clinical significance
TRAb Assays
TRAb Assays
TRAb Assays
Hashimoto’s Thyroiditis (HT)

- MCC of hypothyroidism in iodine sufficient areas of the world
- Dr. Hashimoto first described *struma lymphomatosa*, an intense infiltration of lymphocytes within the thyroid
- Characterized by gradual thyroid failure due to autoimmune mediated destruction of the thyroid gland
- Symptoms: fatigue, weight gain, increased sensitivity to cold, difficulty concentrating, dry skin/nails/hair, constipation, drowsiness, muscle soreness, increased menstrual flow
  - More likely to develop in Pts with another autoimmune disease
- High concentrations of Abs against one or more thyroid antigens; diffuse lymphocytic infiltration of the thyroid (thyroid specific B & T cells) & follicular destruction (hallmark of thyroiditis)
- HT may lead to hypothyroidism or subclinical hypothyroidism (inc TSH and normal TH levels)
- Autoantibodies: blocking TSHR Abs, TG Abs, TPO Abs
Hashimoto’s Encephalitis (HE) & Thyroid Disease

• Does not appear to be directly related to hypo or hyperthyroidism
  • 23-35% pts had subclinical hypothyroidism, 17-20% hypothyroidism, 7% hyperthyroid, remainder were euthyroid (Ferracci & Carnivale 2006)

• The relationship between Hashimoto’s thyroiditis and HE is unclear

• Elevated anti-thyroid Abs (TPO-Ab, TG-Ab) are seen, but also seen in healthy populations
  • There is no relationship between Ab concentration & severity of neurologic symptoms

• Ab levels usually decrease following treatment & clinical improvement (but not always)
Table 1 Symptoms recorded in 121 patients with of HE

<table>
<thead>
<tr>
<th>Symptoms</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizures</td>
<td>63 (52%)</td>
</tr>
<tr>
<td>Confusion</td>
<td>52 (43%)</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>45 (37%)</td>
</tr>
<tr>
<td>Cognitive impairment</td>
<td>44 (36%)</td>
</tr>
<tr>
<td>Altered consciousness</td>
<td>44 (36%)</td>
</tr>
<tr>
<td>Ataxia</td>
<td>40 (33%)</td>
</tr>
<tr>
<td>Focal deficits</td>
<td>37 (31%)</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>36 (30%)</td>
</tr>
<tr>
<td>Tremor</td>
<td>34 (28%)</td>
</tr>
<tr>
<td>Hallucinations</td>
<td>31 (26%)</td>
</tr>
<tr>
<td>Pyramidal signs</td>
<td>25 (21%)</td>
</tr>
<tr>
<td>Headache</td>
<td>16 (13%)</td>
</tr>
<tr>
<td>Extrapyramidal symptoms</td>
<td>13 (11%)</td>
</tr>
<tr>
<td>Cerebellar symptoms</td>
<td>6 (5%)</td>
</tr>
<tr>
<td>Vertigo</td>
<td>4 (3%)</td>
</tr>
<tr>
<td>Myelopathy</td>
<td>3 (2%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>2 (2%)</td>
</tr>
</tbody>
</table>
Pathophysiology of HE

- Autoimmune vasculitis or other inflammatory process, perhaps associated with immune complex deposition, and possibly disrupting the cerebral microvasculature.
- Antibodies thought to cross BBB and react with brain antigens causing encephalopathy, bind to cerebellar astrocytes, anti-thyroid antibodies found in CSF (not in all patients).
- Autopsy studies have shown peri-venular and peri-arteriolar lymphocytic infiltrates within leptomeninges & parenchyma, but this has not been consistent.
Treatment of HE

- High dose corticosteroids: Prednisone doses 50—150mg daily have been used
  - High dose IV Methylpred has also been used, but benefit to oral prednisone has not been shown
- Alternative treatments: IVIG, methotrexate, mycophenolate/cellcept, azathioprine, rituximab, cyclophosphamide (case reports); as alternative treatment, or in patients refractory to steroids or with relapses
Back to Our Patient

- Endo recs:
  - “[HE] is a diagnosis of exclusion and other etiologies of altered mental status should be ruled out prior to making this diagnosis (toxic metabolic encephalopathies, infection, CJD, psychiatric disease, malignancy, paraneoplastic syndrome, dementia, vasculitis, etc)

- If other etiologies are ruled out, can consider treatment for Hashimoto's encephalopathy with corticosteroids - Prednisone 60mg daily (1mg/kg)”
Can HE be diagnosed accurately?

- Most published case reports of HE comprise a very small sample, and there is no comprehensive statistical analysis of the clinical features associated with HE.
- HE remains problematic regarding its pathophysiology, diagnosis, and treatment.
- HE is a diagnosis of exclusion, but important to recognize as it’s prognosis is generally good with steroid treatment.
A case control study to analyze HE characteristics

Cognitive Impairments in Hashimoto’s Encephalopathy: A Case-Control Study

Jianhong Wang1*, Jun Zhang2*, Lan Xu1*, Yunbo Shi1, Xunyi Wu1*, Qihao Guo1*

1Department of Neurology, Huashan Hospital, State Key Laboratory of Medical Neurobiology, Shanghai Medical College, Fudan University, Shanghai, China, 2Department of Radiology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China

Abstract

Background/Aims: Hashimoto’s encephalopathy is considered as a treatable dementia, but it is often misdiagnosed. We investigated cognitive impairment and the MRI pathology of Hashimoto’s encephalopathy patients.

Methods: The study comprised eight patients with Hashimoto’s encephalopathy, 16 patients with mild Alzheimer’s disease and 24 healthy subjects. A neuropsychological battery included assessments of memory, language, attention, executive function and visuospatial ability. Cranial MRI was obtained from all Hashimoto’s encephalopathy patients.
<table>
<thead>
<tr>
<th>Index</th>
<th>HE group (n=8)</th>
<th>Normal group (n=24)</th>
<th>mild AD group (n=16)</th>
<th>F(\chi^2) value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>38.88±11.57</td>
<td>60.25±6.64*</td>
<td>60.44±5.76</td>
<td>28.204</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Years of Education</td>
<td>12.50±2.45</td>
<td>13.38±2.39</td>
<td>11.38±3.20</td>
<td>2.642</td>
<td>0.082</td>
</tr>
<tr>
<td>Gender(M:F)a</td>
<td>5:3</td>
<td>5:11</td>
<td>15:9</td>
<td>4.087</td>
<td>0.130</td>
</tr>
<tr>
<td>MMSE Total score</td>
<td>21.63±1.51</td>
<td>28.75±1.19*</td>
<td>23.31±2.94</td>
<td>56.586</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CESD</td>
<td>7.58±3.47</td>
<td>9.16±7.99</td>
<td>9.00±5.07</td>
<td>0.197</td>
<td>0.898</td>
</tr>
</tbody>
</table>

CES-D = Center for Epidemiologic Studies Depression Scale.
\( a = \chi^2 \) analysis.

\(* = P<0.01\), normal group vs. HE group.

doi:10.1371/journal.pone.0055758.t001
<table>
<thead>
<tr>
<th>Case</th>
<th>Age (yrs)</th>
<th>Sex</th>
<th>Clinical presentation</th>
<th>Special examinations</th>
<th>Treatment</th>
<th>Evolution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>58</td>
<td>F</td>
<td>Partial complex seizures, cognitive impairment</td>
<td>Hippocampus swelling and N angio, EEG diffuse slowing, sharp waves&gt;left</td>
<td>A, S</td>
<td>Occasional relapses, then stable</td>
</tr>
<tr>
<td>2</td>
<td>47</td>
<td>F</td>
<td>Partial complex and generalized seizures, cognitive impairment</td>
<td>MRI bilateral medial temporal and hippocampus FLAIR hypersignal, EEG diffuse slowing, sharp waves&gt;right</td>
<td>A, S</td>
<td>Improvement after ttt</td>
</tr>
<tr>
<td>3</td>
<td>41</td>
<td>F</td>
<td>Cognitive impairment, apathy</td>
<td>MRI white matter alterations, N EEG</td>
<td>S</td>
<td>Improvement after ttt, persistent mild cognitive impairment</td>
</tr>
<tr>
<td>4</td>
<td>24</td>
<td>F</td>
<td>Focal and generalized seizures, cognitive impairment</td>
<td>MRI left medial temporal and amygdala FLAIR hypersignal, N EEG</td>
<td>A,S</td>
<td>Improvement after ttt, seizure free</td>
</tr>
<tr>
<td>5</td>
<td>38</td>
<td>M</td>
<td>Cognitive impairment, anxiety</td>
<td>Hippocampus mild swelling, EEG delta slowing</td>
<td>S, T4</td>
<td>Slight improvement after ttt</td>
</tr>
<tr>
<td>6</td>
<td>46</td>
<td>M</td>
<td>Generalized seizures, cognitive impairment</td>
<td>Hippocampus mild swelling, EEG slowing</td>
<td>S</td>
<td>Improvement after ttt, no seizure relapse</td>
</tr>
<tr>
<td>7</td>
<td>31</td>
<td>F</td>
<td>Cognitive impairment, occasional stupor</td>
<td>MRI white matter alteration, EEG diffuse slowing</td>
<td>S</td>
<td>Significant improvement after ttt, relapses</td>
</tr>
<tr>
<td>8</td>
<td>26</td>
<td>M</td>
<td>cognitive impairment</td>
<td>Hippocampus well-stacked, N EEG</td>
<td>S</td>
<td>Improvement after ttt</td>
</tr>
</tbody>
</table>

N, normal; angio, cerebral angiography; CT, computed tomography; EEG, electroencephalogram; MRI, magnetic resonance imaging; S, steroid; A, anticonvulsant; t, treatment; T4, levothyroxin.
doi:10.1371/journal.pone.0055758.t002
Results From This Study

- Scores from HE group were worse than those of normal control group in most tests
- There was no significant difference in performance between HE and AD group except HE patients showed preserved long term semantic memory (naming ability)
- Pts cognitive function improved with steroid treatment (MMSE scored improved to 28-30/30 from mean of 21.6)
- MRI pathology revealed no involvement of the temporal cortex (which plays a role in naming ability)
- MRI revealed two types of HE manifestation:
  - Leukoencephalopathy type
  - Limbic encephalitis-like type
Figure 2. Limbic encephalitis-like manifestations on MRI images. (A) Coronal MRI image shows bilateral medial temporal and hippocampus hypersignal on FLAIR. (B) Axial MRI image shows left medial temporal and amygdala hypersignal on FLAIR.
Figure 1. Leukoencephalopathy-like manifestations on MRI images. (A, B) Axial MRI images demonstrate widespread periventricular hyperintense signals in the cerebral white matter.
Patient MRI

Looks like leukocencephalopathy like changes, but also looks like chronic ischemic vessel disease.
Impression: Abnormal signal intensity involving the right occipital, right temporal, and right parietal lobe gyri as well as the posterior right thalamus as detailed above. Findings raise the possibility of encephalitis, potentially infectious including viral etiologies, as well as Creutzfeldt-Jakob disease.
Back to Our Patient

- Encephalopathy autoimmune eval, CSF NEGATIVE
- Paraneoplastic panel: NEGATIVE
- Infectious encephalitis panel: NEGATIVE
- Continued to have seizures, tongue sticking out w R gaze preference
- Diagnosed with encephalitis of undetermined etiology, steroids started (60mg prednisone + 1g methylpred Qd) and IVIG started on 8/24
- Course: able to speak own name -> catatonia -> following simple commands -> catatonia -> intermittently continued having seizures
PET Scan (Hx of breast cancer)

IMPRESSION:
1. No evidence of FDG avid tumor. The subpleural nodule in the right middle lobe is not FDG avid, which is most likely benign. However indolent tumor cannot be excluded. Suggest follow-up with CT.

2. Diffuse increased metabolic activity in the enlarged thyroid gland is most likely due to thyroiditis.

3. Inflammatory changes in the lower lungs/pleurae and bilateral gluteal regions.

4. Postprocedural changes in the left upper abdominal wall.
Continued Patient Course: Exam on 9/4/17

Constitutional: lying in bed, responds to voice
HEENT: does not open eyes on command
Neck: mild thyromegaly, no acanthosis nigricans
Cardiovascular: regular rate and rhythm, nml S1/S2
Pulmonary/Chest: clear to auscultation bilaterally
Abdomen: soft
Extremities: no edema
Neurological: not alert, stiff R arm, does not move extremities, unable to obtain reflexes
Skin: warm, dry
Other: GI tube with bloody output
Continued Patient Course

- Prednisone 40-60mg 8/24 – 8/27
- Methylprednisolone 1g IV 8/25- 9/3
- IVIG 8/24 – 8/28
- Ativan started for catatonia, Psych involved
- Solumedrol IV 30mg 9/4– close to discharge
- Discharged on 40mg prednisone on 9/15/17 (as well as seizure meds)
- Follow up chest CT showed stable lung nodule several months later
- TSH normalized a few months later
Clinic visit on 11/7/17

“Significantly improved. She still has occasional visual hallucinations, consisting of seeing her cat when the cat is not actually there. She possibly has auditory hallucinations at night and hears people talking. Catatonia significantly improved yet son describes that patient's arm "occasionally gets stuck in one position". Other complaint is depression, and patient "feels like crying in the morning upon waking up"
Clinic visit 07/17/18

“Patient has been doing well overall. She lives at home with her son and they have assistance Mon-Fri and additional resources if they need them. She is currently taking Ativan 0.5 mg TID, prednisone 30 mg daily, and Keppra 750 mg BID. Phenytoin has been tapered off. Son notes that that she is doing well, has intermittent mild hallucinations, although they have much improved. They obtained a pneumonia shot recently from their PCP in preparation of initiation of Cellcept.”
Conclusions

• HE is an autoimmune disorder that is associated with thyroid antibodies (anti-TPO and/or anti-TG), but not due to thyroid disease

• TRAbs include stimulating TSHR Abs (detected by TSI) and TSH blocking and neutral Abs (all 3 detected by TRAb assay)

• The presentation of HE is heterogenous with a fulminant, subacute or more chronic course of declining mental status that is frequently accompanied by seizures, myoclonus and psychiatric symptoms

• The presence of elevated anti-thyroid Abs and exclusion of other causes of encephalopathy support its diagnosis

• MRI findings for HE are not specific or sensitive

• Prognosis of HE is generally good with steroid treatment. Other immunosuppressive therapies can be used in patients who are refractory to steroids or relapse

• Pt improved with steroid therapy (now 1+ year) to be transitioned to Cellcept
References


Thyroid Hormone Synthesis